Elizabeth Gourd
Elizabeth Gourd
Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study [0.03%]
人工智能辅助的胸膜间皮瘤体积反应标准（ARTIMES）的发展与验证：一项多队列、多中心回顾性研究
Kevin B W Groot Lipman,Rianne Wittenberg,Mateus de Oliveira Taveira et al.
Kevin B W Groot Lipman et al.
Background: Response evaluation in pleural mesothelioma is challenging because its crescent growth pattern is poorly captured by diameter-based criteria. We aimed to develop and validate artificial intelligence (AI)-assis...
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial [0.03%]
甲磺酸奥美替尼联合化疗对比单用化疗治疗EGFR突变阳性晚期非小细胞肺癌患者的随机、对照、多中心Ⅲ期临床研究(AENEAS2)
Ziming Li,Jie Hu,Jianhua Chen et al.
Ziming Li et al.
Background: Although third-generation epidermal growth-factor receptor (EGFR)-tyrosine-kinase inhibitors (TKIs) are standard first-line therapies for patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC),...
Treatment-related adverse events of CD3-based T cell-engaging bispecific antibodies in patients with cancer: a meta-analysis of clinical trials [0.03%]
基于CD3的双特异性抗体治疗在癌性患者中引发的相关不良事件：临床试验meta分析研究
Youwen Zhu,Kun Liu,Steven T Rosen et al.
Youwen Zhu et al.
Background: Clinical trials evaluating CD3-based T cell-engaging bispecific antibodies for cancer therapy have rapidly progressed from early investigations to clinical application. As these agents enter practice, it is es...
Barbara Casassus
Barbara Casassus
Elizabeth Gourd
Elizabeth Gourd